What do we know about the α/β for prostate cancer?

Research output: Contribution to journalReview articlepeer-review

26 Citations (Scopus)


Since last decade, the debate on the parameter which reflects prostate cancer sensitivity to fractionation in a radiotherapy treatment, the α/β, has become extensive. Unlike most tumors, the low labeling indices (LI) and large potential doubling time that characterize the prostate tumor led some authors to consider that it may behave as a late responding tissue. So far, the existing studies with regard to this subject point to a low value of α/β, around 2.7 Gy, which may be considered as a therapeutic gain in relation to surrounding normal tissues by using fewer and larger fractions. The aim of this paper is to review several estimates that have been made in the last few years regarding the prostate cancer α/β both from clinical and experimental data, as well as the set of factors that have potentially influenced these evaluations. © 2012 American Association of Physicists in Medicine.
Original languageEnglish
Pages (from-to)3189-3201
Number of pages13
JournalMedical Physics
Issue number6
Publication statusPublished - 2012


  • alpha/beta ratio
  • prostate cancer
  • radiobiology
  • radiotherapy


Dive into the research topics of 'What do we know about the α/β for prostate cancer?'. Together they form a unique fingerprint.

Cite this